# A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

Study · id `cardio:ct-nct04736628` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04736628](<https://clinicaltrials.gov/study/NCT04736628>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04736628

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 261 participants.

## Technical summary

Registry record NCT04736628. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-27 (actual); primary completion 2023-08-15 (actual). Results posted on 2024-09-04.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 261 participants (enrolled count; ClinicalTrials.gov record NCT04736628, source copy `cardio:ctgov-nct04736628-2024-09-04`, retrieved 2026-10-26)
- Started: 2021-04-27 (actual) (ClinicalTrials.gov record NCT04736628, source copy `cardio:ctgov-nct04736628-2024-09-04`, retrieved 2026-10-26)
- Primary completion: 2023-08-15 (actual) (ClinicalTrials.gov record NCT04736628, source copy `cardio:ctgov-nct04736628-2024-09-04`, retrieved 2026-10-26)
- Completion: 2023-09-21 (actual) (ClinicalTrials.gov record NCT04736628, source copy `cardio:ctgov-nct04736628-2024-09-04`, retrieved 2026-10-26)
- Results first posted: 2024-09-04 (ClinicalTrials.gov record NCT04736628, source copy `cardio:ctgov-nct04736628-2024-09-04`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Canada; China; Denmark; Germany; Hong Kong SAR China; Japan; Malaysia; Mexico; New Zealand; Poland; Portugal; Russia; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT04736628, source copy `cardio:ctgov-nct04736628-2024-09-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04736628-2024-09-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
- Condition: Chronic Kidney Disease
- Intervention (Drug): Avenciguat
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 832a358f83f3b6f194110dd41f9c12f01cbcb2b9a6b62373776978f4a8317490
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
